European Orphan Designations granted to CF102 and ENMD-2076

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Medicines Agency granted an Orphan Drug Designation to ENMD-2076, developed by CASI Pharmaceuticals Inc., for the treatment of hepatocellular carcinoma, including fibrolamellar carcinoma, a rare type of HCC.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login